Floatz logo

Blinatumomab

Childhood Acute Lymphoblastic Leukemia

Institute of Hematology & Blood Diseases Hospital, Chinamonoclonal_antibodyPhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
89/ 100

Competitive context

64 Active assets in the Childhood Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
Vincristine Sulfate
National Cancer Institute (NCI)
Phase 3BBB
Methotrexate
Children's Oncology Group
Phase 3BBB
Nivestim
St. Jude Children's Research Hospital
Phase 3BBB
Cytarabine
Children's Oncology Group
Phase 3BBB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 3BBB

View all 50 →

Same molecule, other indications

Blinatumomab is also rated in:

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Active
BBB
Indicative · Phase 3
72 / 100
View asset →
precursor B-cell acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 3
72 / 100
View asset →
B-cell acute lymphoblastic leukemiaActive
BB
Indicative · Phase 4
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →